Myocardial changes after spironolactone in spontaneous hypertensive rats. A laser scanning confocal microscopy study

Journal of Cellular and Molecular Medicine

Volumn 6, Issue 1, 2002, Pages 49-57

  Pereira, Leila Maria Meirelles ^a   Mandarim De Lacerda, Carlos Alberto ^a  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Confocal microscopy; Enalapril; Hypertension; Spironolactone; Verapamil

Indexed keywords

ALDOSTERONE ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; SPIRONOLACTONE; VERAPAMIL;

ANIMAL; ARTICLE; BLOOD PRESSURE; CARDIOMEGALY; CONFOCAL MICROSCOPY; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECT; HEART; HEART MUSCLE; HYPERTENSION; MALE; PATHOLOGY; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; STATISTICS;

ALDOSTERONE ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CARDIOMEGALY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ENALAPRIL; HEART; HYPERTENSION; MALE; MICROSCOPY, CONFOCAL; MYOCARDIUM; RATS; RATS, INBRED SHR; SPIRONOLACTONE; STATISTICS; VERAPAMIL;

EID: 0036361571     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2002.tb00310.x     Document Type: Article

References (26)

1. Brilla C.G., Pick R., Tan L.B., Janick J.S., Weber K.T., Remodeling of the rat right and left ventricle in experimental hypertension, Circ. Res., 67: 1355-1364, 1990
2. Sun Y., Weber K.T., Cardiac remodelling by fibrous tissue: role of local factors and circulating hormones, Ann. Med., 30:(Suppl. 1), 3-8, 1998
3. Lijnen P., Petrov V., Antagonism of the renin-angiotensin- ALDO system and collagen metabolism in cardiac fibroblasts, Method Find Exp. Clin. Pharmacol., 21: 215-227, 1999
4. Lijnen P., Petrov V., Induction of cardiac fibrosis by aldosterone, J. Mol. Cell. Cardiol., 32: 865-879, 2000
5. Dixon I.M., Ju H., Reid N.L., Scammell-La Fleur T., Werner J.P., Jasmin G., Cardiac collagen remodelling in the cardiomyopathic Syrian hamster and the effect of losartan, J. Mol. Cell. Cardiol., 29: 1837-1850, 1997
6. Brilla C.G., Matsubara L.S., Weber K.T., Anti-ALDO treatment and prevention of myocardial fibrosis in primary and secondary hyperaldosteronism, J. Mol. Cell. Cardiol., 25: 563-575, 1993
7. Robert V., Silvestre J.S., Charlemagne D., et al., Biological determinants of aldosterone-induced cardiac fibrosis in rats, Hypertension, 26[Part 1]: 971-978, 1995
8. Brilla C.G., Aldosterone and myocardial fibrosis in heart failure, Herz. 25: 299-306, 2000
9. Brilla C.G., Weber K.T., Reactive and reparative myocardial fibrosis in arterial hypertension in the rat, Cardiovasc. Res., 26: 671-677, 1992
10. Young M., Head G., Funder J., Determinants of cardiac fibrosis in experimental hypermineralocorticoid states, Am. J. Physiol., 269: E657-E662, 1995
11. Pitt B., Zannad F., Remme W., et al., The effect of spironolactone on morbidity and mortality in patients with severe heart failure, New Engl. J. Med., 341: 709-717, 1999
12. Maish B., Brilla C., Kruse T., Directions in antihypertensive treatment - our future from the past, Eur. Heart J., 16: (Suppl C), 74-83, 1995
13. Weber K.T., Cardioreparation in hypertensive heart disease, Hypertension, 38: (Part 2), 588-591, 2001
14. R.A.L.E.S. Study, Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the randomized aldactone evaluation study [RALES]), Am. J. Cardiol., 78: 902-907, 1996
15. Dolber P.C., Spach M.S., Picrosirius red staining of cardiac muscle following phosmolybdic acid treatment, Stain Tech., 62: 23-26, 1987
16. Dolber P.C., Spach M.S., Conventional and confocal fluorescence microscopy of collagen fibers in the heart, J. Histotechnol. Cytochem., 41: 465-469, 1993
17. Zar J.H., Biostatistical analysis, Upper Saddle River: Prentice Hall, 1999
18. Lacolley P., Safar M.R., Lucet B., Ledudal K., Labat C., Benetos A., Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats, J. Am. Coll. Cardiol., 37: 662-667, 2001
19. Takeda Y., Yoneda T., Demura M., Miyamori I., Mabuchi H., Cardiac aldosterone production in genetically hypertensive rats, Hypertension, 36: 495-500, 2000
20. Brown L., Duce B., Miric G., Sernia C., Reversal of cardiac fibrosis in deoxycortcosterone acetate-salt hypertensive rats by inhibition of the rennin-angiotensin system, J. Am. Soc. Nephrol., 10: S143-S148, 1999
21. Miric G., Dallemagne C., Endre Z., Margolin S., Taylor S.M., Brown L., Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats, Br. J. Pharmacol., 133: 687-694, 2001
22. Ramires F.J.A., Sun Y., Weber K.T., Myocardial fibrosis associated with ALDO or angiotensin II administration: attenuation by calcium channel blockade. J. Mol. Cell. Cardiol., 30: 475-483, 1998
23. Sadoshima J., Izumo S., Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype, Cir. Res., 73: 413-423, 1993
24. 2 receptors prevents the increase in capillary density induced by chronic angiotensin-converting enzyme treatment in stroke-prone spontaneously hypertensive rats, Hypertension, 29: 478-482, 1997
25. Unger T., Mattfeld T., Lamberty V., Bock P., Mall G., Linz W., Effect of early onset angiotensin converting enzyme inhibition on myocardial capillaries, Hypertension, 20: 478-482, 1992
26. Pereira L.M.M., Mandarim-de-Lacerda C.A., The effect of enalapril and verapamil on the left ventricular hypertrophy and the left ventricular cardiomyocyte numerical density in rats submitted to nitric oxide inhibition, Int. J. Exp. Path., 82: 115-122, 2001